On January 27th, STENOCARE A/S (“STENOCARE” or “the Company”) announced that the Company has entered a strategic partnership with WEECO Pharma GmbH to launch premium medical cannabis oils in Germany. The first new product under the collaboration will be called “WEECO ASTRUM 10-10 extract” and will be available for patients during February 2026.
Analyst Group’s View of the News
STENOCARE has had the Company’s premium medical cannabis product available for patients in Germany since January 2025, a product called ”Astrum 10-10 Oil Stenocare”. The newly launched WEECO ASTRUM 10-10 extract is expected to be a similar product, containing 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle, but re-branded. Analyst Group expects that the Stenocare-branded product will be out phased out for the benefit of the new WEECO-branded product.
The rationale for this is that WEECO contributes extensive experience in navigating regulatory frameworks, providing pharmaceutical advisory services, and executing sales, distribution, and product registrations for medical cannabis in both the German market and internationally. Hence, we view the collaboration as a strategic initiative to increase awareness and reach of STENOCARE’s innovative premium medical cannabis oil in Germany, while also possibly open doors to launch the Astrum oil on new markets, as it is only currently available in Germany, Norway and Australia.
In the Q3-25 report, STENOCARE stated that “Astrum 10-10 Oil Stenocare” was being prescribed to patients. The collaboration with WEECO is expected to further accelerate sales by leveraging Astrum oil under the brand of a well-established player in the German medical cannabis distribution market. Moreover, Germany is one of the most important and largest medical cannabis markets in Europe, which makes a successful commercialization of the Astrum oil an important value driver going forward.
The Astrum oil is viewed as a key growth driver throughout the coming years through its competitive advantages. The product is not yet assumed to have contributed significantly to the sales growth in 2025. The introduction of new products typically takes time, as the European medical cannabis market remains relatively young, and both the market and prescribing physicians require further education on the products’ benefits, an area in which STENOCARE is actively engaged. Nevertheless, the product is now gaining traction, and STENOCARE has received encouraging feedback from the market. We therefore expect a gradual increase in sales over the coming periods.
The Benefits of the Astrum Oil
Doctors encounter challenges when prescribing medical cannabis to patients due to the body’s metabolism, which significantly reduces the uptake of cannabinoids to approximately 15%. This results in only a variable and often minimal portion of the cannabinoids being actively delivered to the body with therapeutic effect, meaning an inconsistent uptake of the active ingredients into the blood. Additionally, the absorption by the body varies from person to person and depending on whether the medication is taken before or after food consumption. This variability leads to unpredictable effects and complicates the doctors’ ability to prescribe the correct dosage.
STENOCARE’s new Astrum oil addresses all these problems as it is based on new innovative oil technology. The product differentiates STENOCARE as a first mover in the next generation of medical cannabis, providing improved, uniform, and faster uptake in the bloodstream.
About WEECO Pharma GmbH
WEECO is a Germany-based pharmaceutical company focused on the development, marketing, and distribution of prescription and non-prescription products. The company has an established commercial platform in the DACH region, with strength in local market access, regulatory expertise, and branded distribution within the German healthcare market.
In summary, Analyst Group views STENOCARE’s partnership with WEECO Pharma and the launch of the WEECO ASTRUM 10-10 extract in Germany as a strategically important step to accelerate the commercialization of the Company’s premium Astrum oil. By leveraging WEECO’s established position, regulatory expertise, and sales and distribution capabilities in the German medical cannabis market, STENOCARE is expected to increase awareness, market penetration, and prescribing activity for Astrum oil. Germany represents one of the largest and most important medical cannabis markets in Europe, making a successful rollout a key value driver going forward.
